Deals this week: ITL Biomedical, Senzime AB, Abryx Inc

8 December 2016 (Last Updated December 8th, 2016 18:30)

ITL Biomedical and BioMerieux Canada have entered into a distribution agreement to further develop ITL Biomedical’s Saftey SubCulture Unit (SCU).

ITL Biomedical and BioMerieux Canada have entered into a distribution agreement to further develop ITL Biomedical’s Saftey SubCulture Unit (SCU).

The agreement enables the two medical device companies to safely transfer bacteria positive samples through the SCU for further testing.

Senzime AB and Fukuda Denish Co. Ltd have entered a licensing agreement to commercialise Senzime’s TetraGraph system in Japan.

"The agreement enables the two partners to launch Senzime’s TetraGraph system in Japan by the end of 2017."

According to the agreement, Senzime will receive $106.61m as license revenue-related milestones and royalties payments.

The agreement enables the two partners to launch Senzime’s TetraGraph system in Japan by the end of 2017.

Abryx Inc, a biosurgical products provider, has raised $10m in an equity financing round led by Canaan Partners, Mededge Inc and BB Biotech Ventures.

The company plans to invest the funds to handle the demand for its bone putty products and also to further develop its pipeline products.

Essex Woodlands Management Inc. has invested $15m in Metabolon, a medical diagnostics and services provider.

The company plans to invest the funds to repurchase a few shares that are held by existing investors.